relapsed or refractory diffuse large B-cell lymphoma

Roche follows AbbVie with FDA approval for dual-targeting lymphoma drug
BioPharma Dive
Fri, 06/16/23 - 09:57 am
Roche
Columvi
FDA
relapsed or refractory diffuse large B-cell lymphoma
blood cancer
Gilead's Kite earns second-line win for CAR-T Yescarta, setting up a battle over earlier blood cancer patients
Endpoints
Mon, 06/28/21 - 10:51 am
Gilead Sciences
Kite Pharma
Yescarta
relapsed or refractory diffuse large B-cell lymphoma
CAR-T
ADC Therapeutics gets the nod from the FDA for its CD19-targeted antibody drug conjugate
Biopharma Reporter
Mon, 04/26/21 - 11:55 am
ADC Therapeutics
Zynlonta
antibody-drug conjugate
FDA
relapsed or refractory diffuse large B-cell lymphoma
ADC gets priority review for anti-CD19 blood cancer drug
Fierce Biotech
Fri, 11/20/20 - 11:12 am
FDA
ADC Therapeutics
antibody-drug conjugate
Lonca
relapsed or refractory diffuse large B-cell lymphoma
Daiichi Sankyo submits application for CAR T therapy axicabtagene ciloleucel to treat patients with certain relapsed/refractory B-cell lymphomas in Japan
Pharmaceutical Business Review
Tue, 03/31/20 - 11:05 am
Daiichi Sankyo
Japan
CAR-T
axicabtagene ciloleucel
relapsed or refractory diffuse large B-cell lymphoma
Gilead highlights Yescarta survival data in ASCO update
Pharmaforum
Mon, 06/3/19 - 07:46 pm
Gilead Sciences
clinical trials
Yescarta
relapsed or refractory diffuse large B-cell lymphoma
ASCO 2019
As generic competition stutter sales of top oncology drugs, Roche secures speedy review for pair of experimental cancer offerings
Endpoints
Tue, 02/19/19 - 12:15 pm
Roche
Seattle Genetics
generics
antibody-drug conjugate
polatuzumab vedotin
relapsed or refractory diffuse large B-cell lymphoma
entrectinib
solid tumors